Friday, February 29, 2008 5:38:47 PM
i know - my point was more along the lines of what clark said when he posted "The most powerful thing going for this trial that is clear from the data WE have is that it is that the drug clearly stops menses - and it seems improbable that that wouldn't have a significant effect on anemia." - i would jsut add that another powerful thing going is that pts with heavy bleeding from fibroids continue to have heavy bleeding when given a placebo. when i look at the chance a drug may not act the same in a ph 3 compared with a ph 2, believability of the moa and efficacy factors in - as you alluded to in a post, jsut taking statistical modeling into account some % of trials in ph 2 will show enough efficacy to move to ph 3 despite that drug having zero efficacy - and that % is more than 5 i might add (and i know you know) because all one needs is enough of a signal - a trend - and not a .05 p-threshold to move to ph 3. i bet if you bothered to look at a distribution of drug performance in ph 3 compared to ph 2, that distribution is skewed bimodally, with a peak at no efficacy (for htose drugs that made it through to ph 3 by cahnce) and a peak at equal efficacy, where i woudl bet you woudl find a preponderance of drugs with establshed MOAs, hard endpoints met in ph 2, etc. so simply stated i belive proellex falls into the latter category, effiacy WILL be comparable to ph 2, and perhaps as important given teh small size of the placebo arm, i believe the placebo arm will perform similarly to the ph 2 as well
Recent RPRX News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/23/2026 08:43:18 PM
- Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence • GlobeNewswire Inc. • 03/23/2026 11:15:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 09:12:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2026 10:02:29 PM
- Royalty Pharma Announces Expansion of Leadership Team • GlobeNewswire Inc. • 03/17/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:11:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:52:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:26:17 PM
- Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:10:00 AM
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:01:00 AM
- Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:08:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 10:06:45 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/20/2026 09:27:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:03:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 02:04:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 12:37:12 PM
- Royalty Pharma Reports Q4 and Full Year 2025 Results • GlobeNewswire Inc. • 02/11/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 10:07:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/03/2026 10:31:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2026 10:28:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:10:58 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
